Aristizabal S A, Caldwell W L
Cancer. 1976 Jun;37(6):2630-5. doi: 10.1002/1097-0142(197606)37:6<2630::aid-cncr2820370610>3.0.co;2-r.
The possible advantages of a split-course of irradiation in the treatment of patients with locally advanced and/or inoperable carcinoma of the lung were explored in over 200 cases. The patients were separated into two groups with different prognostic factors: Group A, patients with well-differentiated tumors confined to the lung and mediastinum; and Group B, cases with anaplastic tumors and/or supraclavicular metastases, bone erosion, or superior venal caval syndrome. The treatment consisted of 5500-6000 rads tumor dose in 20 to 24 fractions over a period of 7 to 8 weeks with a rest interval of 2 to 4 weeks in the middle. The 3- and 5-year survival figures, 19% and 16%, respectively, in Group A cases, along with the excellent tolerance, suggest that the split-course approach has definite advantages.
在200多例患者中探索了分段照射在治疗局部晚期和/或无法手术的肺癌患者中的潜在优势。患者根据不同的预后因素分为两组:A组,肿瘤分化良好且局限于肺和纵隔的患者;B组,肿瘤间变和/或有锁骨上转移、骨质侵蚀或上腔静脉综合征的病例。治疗包括在7至8周内分20至24次给予5500 - 6000拉德的肿瘤剂量,中间休息2至4周。A组患者的3年和5年生存率分别为19%和16%,且耐受性良好,这表明分段照射方法具有明确的优势。